Excellent suggestion, @Boffin99
Pros of delisting
- invite potential buyer to anchor any offer to the price history
- the tight registry indicates that limited trading would only mildly inconvenience most shareholders if trading is limited
- there could be opportunities to re-list in the future if needed. And, the US market better knows how to value biotech companies
- keeping "under the radar"
- less costs & compliance of operating on an exchange
Cons of delisting
- no exchange trading (only OTC trading)
- no clear share value
- no analyst coverage, and less interest from investors (specially retail)
I am not saying this is necessarily the right think to do, but it is certainly worth discussing. Thoughts anyone?
I'll add this question to the investor briefing next week.
Industry news, page-722
-
- There are more pages in this discussion • 1,004 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |